Chronopin: upcoming release dates, events and other important dates

San Miguel Corporation's New Manila International Airport in Bulacan has seen its first-runway target pushed back to 2028 after a sand shortage stalled land reclamation.

Rubin's Data Release 1, built from the first year of the Legacy Survey of Space and Time, is expected about two years after the survey began on 29 June 2026.

A nuclear-powered rotorcraft that will fly between sites on Saturn's moon Titan, arriving in the 2030s. Scheduled date.

AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Los Angeles hosts its third Games after 1932 and 1984, using almost entirely existing venues.

Los Angeles is preparing to host the 2028 Summer Olympics with zero new venues and a 'no-car' transit plan, a bold bet for a city not known for its public transport.

Totality passes directly over central Sydney for nearly four minutes, the first there since 1857.

Roche's phase 3 trial of Enicepatide in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

The five-year UPS-Teamsters agreement covering some 340,000 workers expires on 31 July 2028, and the union's president has already said a strike is coming.

AstraZeneca's phase 3 trial of AZD6234 in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity.

The 2028 Summer Paralympics, also known as the Los Angeles 2028 Summer Paralympic Games, and branded as LA28, will be the 18th edition of the Summer Paralympic Games, an international multi-sport parasports event governed by the International Paralympic Committee. The Games are scheduled to take place from August 15 to August 27, 2028, in Los Angeles, California, United States. The pin sits at Los Angeles Memorial Coliseum.

Boehringer Ingelheim's phase 3 trial of BI 690517 in kidney disease, chronic reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 11,000 participants. This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation.

Saudi Arabia's Jeddah Tower has passed its 100th floor and is on track to become the world's tallest building, edging past a kilometre in height once its spire is counted.

Time Out brings its market home to the city where the magazine started in 1968: 26,400 square feet over three floors at 10 Piccadilly, on a long-term partnership with The Crown Estate, as the flagship of the whole portfolio.

Cancer, liver-disease and pregnancy warnings become mandatory on every alcohol container sold in Ireland, after the government pushed the start from 22 May 2026 to 3 September 2028 citing economic circumstances.

The 2028 ICC Men's T20 World Cup will be the eleventh edition of the ICC Men's T20 World Cup, co-hosted by Cricket Australia and New Zealand Cricket from 21 October to 19 November 2028. It will be the first time that New Zealand would host the event, while Australia had previously hosted the competition in 2022. The article names no venues, so this pin sits at Melbourne Cricket Ground, the lead host's flagship ground.

Election Day for the 2028 U.S. presidential race is November 7, 2028, and Kalshi's winner market was still wide open on 20 September 2026: J.D. Vance led at 22%, followed by Jon Ossoff at 12% and Marco Rubio at 9.6%. The winner takes office on January 20, 2029.

A 35 km fully underground east-west line beneath Lima, cutting a two-hour surface trip to about 45 minutes. Estimated date.

Pfizer's phase 3 trial of C.Difficile Vaccine in clostridoides difficile associated disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 32,500 participants. The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot into the upper arm muscle. This study looks at the number of diarrhea (loose stools) events related to a C. difficile infection, so the length of the study can change. If these events happen quickly, the study may finish sooner; if they happen slowly, it could take longer. Sometimes, the study might stop early if the vaccine clearly does not work. Participants will stay in the study until enough events have occurred to answer the main question.

Pfizer's phase 3 trial of PG4 in pneumococcal disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,400 participants. The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are two groups in this study. All participants will be assigned to one of the two groups.

Dubai developer Muraba and Pritzker Prize-winner RCR Arquitectes are building Muraba Veil, a 380m tower just 22.5m wide wrapped in a porous steel mesh, among the world's skinniest skyscrapers.